BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day
Rhea-AI Summary
BioArctic (NASDAQ Stockholm: B) reported that partner Eisai presented a simulation of potential future Leqembi sales at its Investor Relations Day.
According to Eisai, simulated Leqembi sales reach around JPY 300 billion (≈SEK 17.6 billion) in FY2028, ending March 2029. The disclosure was made under EU Market Abuse Regulation rules.
AI-generated analysis. Not financial advice.
Positive
- Eisai simulates Leqembi FY2028 sales around JPY 300 billion
- Simulation implies potential Leqembi sales of about SEK 17.6 billion in FY2028
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
While the stock was down 1.45%, peers were mixed: WPM -0.56%, FNV +0.54%, AU -0.54%, AEM -0.69%, KGC -1.07%, suggesting a stock-specific move rather than a uniform sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 15 | Partner sales outlook | Positive | -5.9% | Partner projected higher FY 2026 sales and related royalties from a key product. |
| May 14 | Dividend declaration | Positive | -3.8% | Board approved quarterly cash dividend on both Class A and Class B shares. |
| May 14 | Annual meeting results | Positive | -3.8% | All director nominees elected and key shareholder proposals received strong support. |
| May 13 | Sector valuation update | Positive | -2.1% | Highlight of rising gold valuations and record cash flow and earnings metrics. |
| May 13 | Earnings call invite | Neutral | -2.1% | Announcement of upcoming quarterly report release and investor presentation details. |
Recent news, including positive operational and outlook updates, has often coincided with negative next-day price moves, indicating a pattern of market divergence from seemingly constructive headlines.
Over the last few months, company- and sector-related news has included revenue and royalty projections for a key partnered product, routine corporate actions like a shareholder meeting with all director nominees elected, and strong financial and cash flow figures linked to higher commodity prices. There have also been invitations to earnings presentations and sector commentary on rising valuations. Despite generally constructive fundamentals and governance outcomes, the stock’s 24-hour reactions to these announcements, often in the -2% to -6% range, tended to be negative, underscoring a cautious market tone into news events.
Market Pulse Summary
This announcement highlights a partner’s simulation that projects Leqembi sales reaching about JPY 300 billion (roughly SEK 17.6 billion) in its FY 2028, ending March 2029. It reinforces the perceived long-term commercial opportunity without changing near-term fundamentals. In evaluating this, investors may weigh how prior outlook-related news has been received, then watch for concrete follow-ups such as realized sales, royalty disclosures, and future regulatory or clinical updates that confirm or challenge these assumptions.
Key Terms
eu market abuse regulation regulatory
AI-generated analysis. Not financial advice.
Eisai's presentation can be found on https://www.eisai.com/ir/library/presentations/index.html
This is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on May 25, 2026, at 09:15 CET.
For further information, please contact:
Oskar Bosson, VP Communications and Investor Relations
E-mail: oskar.bosson@bioarctic.com
Telephone: +46 704 107 180
Jenny Ljunggren, External Communications and Investor Relations Manager
E-mail: jenny.ljunggren@bioarctic.com
Telephone: +46 76 013 86 08
About Leqembi® (lecanemab)
Leqembi is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).
Leqembi is approved in 53 countries and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in 7 countries, including the
Since July 2020, Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer's disease meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in Alzheimer's disease and related dementias in the US, funded by the National Institute on Aging, part of the National Institutes of Health. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited Alzheimer's disease (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in
About the collaboration between BioArctic and Eisai
Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody lecanemab back-up for Alzheimer's disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with sales milestones as well as royalties on global sales.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.
[1] Simulation not to be seen as guidance according to Eisai
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
​​​​​​​BioArctic’s partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day |
View original content:https://www.prnewswire.com/news-releases/bioarctics-partner-eisai-presents-sales-simulation-of-potential-future-sales-of-leqembi-at-its-investor-relations-day-302781006.html
SOURCE BioArctic